Regeneron Pharmaceuticals, Inc. (REGN) News

Regeneron Pharmaceuticals, Inc. (REGN): $577.78

-8.57 (-1.46%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add REGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 495

in industry

Filter REGN News Items

REGN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

REGN News Highlights

  • 500 - Internal server error
  • Over the past 27 days, the trend for REGN's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • The most mentioned tickers in articles about REGN are BODY, EDIT and NTLA.

Latest REGN News From Around the Web

Below are the latest news stories about Regeneron Pharmaceuticals Inc that investors may wish to consider to help them evaluate REGN as an investment opportunity.

Global Lymphocyte Activation Gene 3 Protein Market 2021 Future Set to Massive Growth with High CAGR value | Market Players: Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Crescendo Biologics Ltd, Enumeral Biomedical Holdings Inc, GlaxoSmithKline Plc, Icell Kealex Therapeutics, Incyte Corp, MacroGenics Inc, Merck & Co Inc, Novartis AG, Prima BioMed Ltd, Regeneron Pharmaceuticals Inc, S

The report on Global Lymphocyte Activation Gene 3 Protein Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains []

Jumbo News | July 23, 2021

Doctor on the Olympics regarding COVID-19: ‘There are a lot of concerns’

Dr. Shikha Jain, Assistant Professor of Medicine, University of Illinois Chicago, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

Yahoo | July 23, 2021

‘We haven’t seen the high consequence variants yet’: Doctor

Dr. Heather Yeo, SurvivorNet Medical Advisor & Associate Professor of Surgery and Healthcare Policy and Research at Weill Cornell Medical College, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

Yahoo | July 22, 2021

REGN or INCY: Which Is the Better Value Stock Right Now?

REGN vs. INCY: Which Stock Is the Better Value Option?

Yahoo | July 22, 2021

Roche's (RHHBY) 1H21 Sales Rise Despite Impact of Biosimilars

Roche's (RHHBY) performance in first-half 2021 was impressive on strong demand for new medicines and COVID-19 test kits. Impact of biosimilars continues to hurt sales.

Yahoo | July 22, 2021

Regenerons (REGN) Antibody Cocktail for COVID-19 Approved in Japan

Regeneron Pharmaceuticals, Inc. REGN announced that its antibody cocktail, casirivimab and imdevimab, for the treatment of COVID-19 has been approved in Japan. The cocktail, known as REGEN-COV in the United States, was granted full approval in Japan under the name Ronapreve. The antibody cocktail was granted a Special Approval Pathway under article 14-3 of the [] The post Regenerons (REGN) Antibody Cocktail for COVID-19 Approved in Japan appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .

FXNews24 | July 21, 2021

Regeneron (REGN) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Regeneron (REGN) closed at $583.72, marking a -0.6% move from the previous day.

Yahoo | July 21, 2021

‘It’s very premature to talk about booster vaccines’: Doctor

Dr. Amesh Adalja, Senior scholar Johns Hopkins center for health security, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

Yahoo | July 21, 2021

Has Regeneron Pharmaceuticals (REGN) Outpaced Other Medical Stocks This Year?

Is (REGN) Outperforming Other Medical Stocks This Year?

Yahoo | July 21, 2021

Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX

The biotech sector was in focus last week on updates form Regeneron (REGN) and Bristol Myers (BMY).

Yahoo | July 21, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6675 seconds.